Tohoku University

Otsuka Pharmaceutical Company, Limited

Hideki Katagiri

Tetsuya Yamada

Makoto Inada

Kei Takahashi

Keiko Kawata

Kenji Uno

Sohei Tsukita

Kimiyoshi Sudoh

Yoshitomo Oka

An object of the disclosure is to provide a composition for evaluating the hepatic glucose uptake capacity of a subject and a method for evaluating the hepatic glucose uptake capacity of a subject with the composition. An object of the disclosure is to provide a method for determining the stage of pre-onset diabetes in a subject with pre-onset diabetes using the method for evaluating the hepatic glucose uptake capacity. An aspect of the disclosure accordingly provides a composition comprisingC-labeled glucose for evaluating the hepatic glucose uptake capacity of a subject. Another aspect of the disclosure provides a method comprising measuringC-labeled glucose in a blood sample or an expired air sample obtained from the subject to which the composition was administered. The desired evaluation or determination can be achieved by comparing the measured value with a reference value.

Method of evaluating hepatic glucose uptake capacity

The present invention is directed to provide nucleic acid molecules that promote proliferation of pancreatic islet &#x3b2;-cells. A proliferation promoting agent for promoting proliferation of pancreatic islet &#x3b2;-cells according to the present invention contains at least one of a nucleic acid molecule having SEQ ID NO: 1 or a nucleic acid molecule having SEQ ID NO: 2: 

Nucleic acid molecule

A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-&#x3b3;2 function in the liver.

Method for activating efferent sympathetic nerves innervating adipose tissues to improve obesity and symptoms associated therewith

Growing community of inventors

Sendai, Japan

Hideki Katagiri